5 results on '"Yoko Ida"'
Search Results
2. Identification of potent siRNA targeting complement C5 and its robust activity in pre-clinical models of myasthenia gravis and collagen-induced arthritis
- Author
-
Yoshikazu Kuboi, Yuta Suzuki, Sotaro Motoi, Chiyuki Matsui, Naoki Toritsuka, Tomoya Nakatani, Kazuhiro Tahara, Yoshinori Takahashi, Yoko Ida, Ayaka Tomimatsu, Motohiro Soejima, and Toshio Imai
- Subjects
MT: Delivery strategies ,small interfering RNA ,complement component 5 ,lipid nanoparticle ,myasthenia gravis ,collagen-induced arthritis ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Complement component 5 (C5), an important molecule in the complement cascade, blockade by antibodies shows clinical efficacy in treating complement-mediated disorders. However, insufficient blockading induced by single-nucleotide polymorphisms in the C5 protein or frequent development of “breakthrough” intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab have been reported. Herein, we developed a lipid nanoparticle (LNP)-formulated siRNA targeting C5 that was efficiently delivered to the liver and silenced C5 expression. We identified a potent C5-siRNA with an in vitro IC50 of 420 pM and in vivo ED50 of 0.017 mg/kg following a single administration. Single or repeated administrations of the LNP-formulated C5-siRNA allowed robust and durable suppression of liver C5 expression in mice. Complement C5 silencing ameliorated C5b-dependent anti-acetylcholine receptor antibody-induced myasthenia gravis and C5a-dependent collagen-induced arthritis symptoms. Similarly, in nonhuman primates, a single administration of C5-siRNA/LNP-induced dose-dependent plasma C5 suppression and concomitantly inhibited serum complement activity; complement activity recovered to the pre-treatment levels at 65 days post administration, thus indicating that the complement activity can be controlled for a specific period. Our findings provide the foundation for further developing C5-siRNA delivered via LNPs as a potential therapeutic for complement-mediated diseases.
- Published
- 2023
- Full Text
- View/download PDF
3. Accumulation of annexin A2 and S100A10 prevents apoptosis of apically delaminated, transformed epithelial cells.
- Author
-
Shoko Ito, Keisuke Kuromiya, Miho Sekai, Hiroaki Sako, Kazuhito Sai, Riho Morikawa, Yohei Mukai, Yoko Ida, Moe Anzai, Susumu Ishikawa, Kei Kozawa, Takanobu Shirai, Nobuyuki Tanimura, Kenta Sugie, Junichi Ikenouchi, Motoyuki Ogawa, Isao Naguro, Hidenori Ichijo, and Yasuyuki Fujita
- Subjects
EPITHELIAL cells ,ANNEXINS ,APOPTOSIS ,EPITHELIUM ,REACTIVE oxygen species - Abstract
In various epithelial tissues, the epithelial monolayer acts as a barrier. To fulfill its function, the structural integrity of the epithelium is tightly controlled. When normal epithelial cells detach from the basal substratum and delaminate into the apical lumen, the apically extruded cells undergo apoptosis, which is termed anoikis. In contrast, transformed cells often become resistant to anoikis and able to survive and grow in the apical luminal space, leading to the formation of multilayered structures, which can be observed at the early stage of carcinogenesis. However, the underlying molecular mechanisms still remain elusive. In this study, we first demonstrate that S100A10 and ANXA2 (Annexin A2) accumulate in apically extruded, transformed cells in both various cell culture systems and murine epithelial tissues in vivo. ANXA2 acts upstream of S100A10 accumulation. Knockdown of ANXA2 promotes apoptosis of apically extruded RasV12-transformed cells and suppresses the formation of multilayered epithelia. In addition, the intracellular reactive oxygen species (ROS) are elevated in apically extruded RasV12 cells. Treatment with ROS scavenger Trolox reduces the occurrence of apoptosis of apically extruded ANXA2-knockdown RasV12 cells and restores the formation of multilayered epithelia. Furthermore, ROS-mediated p38MAPK activation is observed in apically delaminated RasV12 cells, and ANXA2 knockdown further enhances the p38MAPK activity. Moreover, the p38MAPK inhibitor promotes the formation of multilayered epithelia of ANXA2-knockdown RasV12 cells. These results indicate that accumulated ANXA2 diminishes the ROS-mediated p38MAPK activation in apically extruded transformed cells, thereby blocking the induction of apoptosis. Hence, ANXA2 can be a potential therapeutic target to prevent multilayered, precancerous lesions. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Construction of Chiral Polar Crystals from Achiral Molecules by Stacking Control of Hydrogen-Bonded Layers Using Type II Halogen Bonds.
- Author
-
Sasaki, Toshiyuki, Yoko Ida, Ichiro Hisaki, Seiji Tsuzuki, Norimitsu Tohnai, Coquerel, Gérard, Hisako Sato, and Mikiji Miyata
- Subjects
- *
CHIRALITY , *HYDROGEN bonding , *HALOGENS , *CHEMICAL potential , *POLARITY (Chemistry) , *DIPOLE moments - Abstract
Crystals belonging to P1 and P21 space groups are fascinating research targets because of their potential applications in various fields by taking advantage of their chirality and polarity. However, molecules intrinsically prefer symmetric, achiral nonpolar space groups due to canceling out of dipole moments and close packing in crystalline states. Therefore, it remains difficult to selectively obtain the P1 and P21 crystals, especially from achiral molecules. Here we achieve construction of the chiral P1 and P21 crystals from achiral molecules based on stacking control of chiral two-dimensional hydrogen-bonded layers by halogen bonds (XBs). Precise investigations and theoretical calculations of their crystal structures revealed that space group selectivity among the chiral P1, P21, and achiral space groups is the result of a subtle balance between the stronger interaction: charge-assisted hydrogen bonds and the weaker interactions: van der Waals interaction of alkyl chains and the bonding involving halogens, which have anisotropic nature and robustness-tunability. It is also noteworthy that type II XBs were observed in chiral crystals, while type I halogen···halogen contacts were formed in achiral crystals, indicating the importance of type II XBs for chiral crystallization. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
5. Clinical Surveillance of Candidemia at Our Hospital.
- Author
-
Akihiko Sano, Yoshifumi Nishi, Shota Yonetani, Hiroaki Yoshida, Hiroko Kawai, Shintaro Homma, Koji Araki, Yoko Ida, Hiroshi Makino, Daisuke Kurai, and Shin Kawai
- Subjects
- *
CANDIDEMIA , *NOSOCOMIAL infections , *ANTIFUNGAL agents , *CANDIDA albicans , *ANTIMICROBIAL stewardship , *DRUG administration - Abstract
Treatment of Candidemia has become increasingly complicated as more and more non-albicans Candida species are being isolated in recent years. We launched an investigation of the species, the MIC value, and the state of administration of antifungal drugs for all the cases with Candida spp. confirmed by blood cultures for the 7-year period from 2012 to 2018 at our hospital. In total, 192 cases were found and 206 strains of Candida species were isolated. Overall, 49.5% of the 206 isolated strains were Candida albicans (102 strains), followed by Candida glabrata (40 strains, 19.4%), and Candida parapsilosis (38 strains, 18.4%). The most frequently used antifungal drug for the initial dose was MCFG (120 cases, 59.2%), while the most frequently switched antifungal agent was L-AMB. Cases with an inappropriate end-of-treatment time represented 58.7% of all the cases. We investigated the Candidemia situation at our hospital for a period of seven years. We believe that it is important for medical institutions to gather detailed data on candidemia at their own hospitals. Likewise, the hospital's Infection Control Team/Antimicrobial Stewardship Team should inform the physicians-in-charge about the appropriate diagnosis and treatment based on the data obtained. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.